Current treatment status of polycystic liver disease in Japan.

Hepatol Res

Department of Surgery, Doctoral Program in Clinical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Published: October 2014

Aim: Polycystic liver disease (PLD) is a genetic disorder characterized by the progressive development of multiple liver cysts. No standardized criteria for the selection of treatment exist because PLD is a rare condition and most patients are asymptomatic. We here aimed to clarify the status of treatment and to present a therapeutic strategy for PLD in Japan.

Methods: From 1 June 2011 to 20 December 2011, we administered a questionnaire to 202 PLD patients from 86 medical institutions nationwide.

Results: The patients included 45 men and 155 women, and the median age was 63 years. Two hundred and eighty-one treatments were performed for these patients, as follows: cyst aspiration sclerotherapy (AS) in 152 cases, cyst fenestration (FN) in 53, liver resection (LR) in 44, liver transplantation (LT) in 13 and other treatments in 19. For cases of type I PLD (mild form) according to Gigot's classification, the therapeutic effects of AS, FN and LR were similar. For type II (moderate form), LT demonstrated the best therapeutic effects, followed by LR and FN. For type III (severe form), the effects of LT were the best. The incidences of complications were 23.0% in AS, 28.4% in FN, 31.8% in LR and 61.5% in LT.

Conclusion: Considering the therapeutic effects and complications, AS, LR and LT showed good results for type I, type II and type III PLD, respectively. However, LT for PLD was performed in a small number of patients. In Japan, the transplantation therapy is expected to be common in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.12286DOI Listing

Publication Analysis

Top Keywords

therapeutic effects
12
polycystic liver
8
liver disease
8
effects type
8
type iii
8
type type
8
pld
7
type
6
liver
5
patients
5

Similar Publications

Real-time monitoring by interferometric light microscopy of phage suspensions for personalised phage therapy.

Sci Rep

December 2024

Pharmacy Department, Hospices Civils de Lyon, Hôpital E. Herriot, Plateforme FRIPHARM, 69437, Lyon, France.

Phage therapy uses viruses (phages) against antibiotic resistance. Tailoring treatments to specific patient strains requires stocks of various highly concentrated purified phages. It, therefore, faces challenges: titration duration and specificity to a phage/bacteria couple; purification affecting stability; and highly concentrated suspensions tending to aggregate.

View Article and Find Full Text PDF

The Epstein-Barr virus (EBV) is widespread and has been related to a variety of malignancies as well as infectious mononucleosis. Despite the lack of a vaccination, antiviral medications offer some therapy alternatives. The EBV BZLF1 gene significantly impacts viral replication and infection severity.

View Article and Find Full Text PDF

Warfarin is the most widely used oral anticoagulant in clinical practice. The cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) genotypes are associated with warfarin dose requirements in China. Accurate genotyping is vital for obtaining reliable genotype-guided warfarin dosing information.

View Article and Find Full Text PDF

To investigate for the risk of uveitis among such patients. A retrospective cohort study utilized the TriNetX database and recruited pediatric autoimmune patients diagnosed between January 1st 2004 and December 31st 2022. The non-autoimmune cohort were randomly selected control patients matched by sex, age, and index year.

View Article and Find Full Text PDF

Ensuring everyone enjoys healthy lifestyles and well-being at all ages, Progress has been made in increasing access to clean water and sanitation facilities and reducing the spread of epidemics and diseases. The synthesis of nano-particles (NPs) by using microalgae is a new nanobiotechnology due to the use of the biomolecular (corona) of microalgae as a capping and reducing agent for NP creation. This investigation explores the capacity of a distinct indigenous microalgal strain to synthesize silver nano-particles (AgNPs), as well as its effectiveness against multi-drug resistant (MDR) bacteria and its ability to degrade Azo dye (Methyl Red) in wastewater.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!